Latest Financial Performance News

Aspermont Limited reported a 6% rise in revenue and a 12% increase in EBITDA for the year ended September 2025, yet posted a net loss of A$2.576 million. The company’s financial health shows mixed signals amid ongoing operational improvements.

DGL Group reported a modest revenue increase in FY25 but faced a sharp decline in profitability, compounded by an auditor’s disclaimer and ERP rollout delays impacting FY26 start.

Prophecy International Holdings reports a modest revenue dip and net loss in FY25, cancels its Complexica merger, and pivots to AI-driven product innovation and cost control.

Platinum Capital Limited’s 2025 AGM marked a pivotal shift as shareholders approved replacing Platinum Investment Management with L1 Capital, aiming to revive the company’s challenged investment performance.

Gale Pacific’s FY25 results show resilience amid tariff challenges, with strategic manufacturing diversification and brand refresh underway to drive future growth.

CD Private Equity Fund III reported a $3.02 million net loss for the half-year ending September 2025, driven largely by foreign currency translation losses, yet maintained a 10 cent per unit distribution supported by portfolio realisations and cash management.

CD Private Equity Fund II reported a reduced net loss of $2.43 million for the half-year to September 2025, supported by $9.45 million in distributions from portfolio realisations. Despite foreign exchange headwinds, the Fund maintains a diversified portfolio and a positive long-term return track record.

CD Private Equity Fund I reported a $2.6 million net loss for the half-year ended 30 September 2025, driven by foreign exchange impacts and fair value adjustments, while distributing 8 cents per unit amid ongoing portfolio realisations.

Vysarn Limited has reported record FY25 profits and is aiming for a 33% NPBT increase in FY26, driven by acquisitions and progress on the Kariyarra Water Scheme. The company is expanding its national footprint amid growing water demand in mining and infrastructure sectors.

Joyce Group reported solid FY25 results with strong revenue growth and a 20% expansion in KWB showrooms, alongside a key leadership transition at KWB.

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Swift Networks reports solid FY25 results with $17.7 million revenue and launches its next-generation Swift TV platform, backed by a recent $1.6 million capital raise and pre-orders across key sectors.